The critical point for successful treatment of cancer is diagnosis at early stages of tumor development. Cancer cell-specific methylated DNA has been found in the blood of cancer patients, indicating that cell-free DNA (cfDNA) circulating in the blood is a convenient tumor-associated DNA marker. Therefore methylated cfDNA can be used as a minimally invasive diagnostic marker. We analysed the concentration of plasma cfDNA and methylation of six tumor suppressor genes in samples of 27 patients with renal cancer and 15 healthy donors as controls. The cfDNA concentrations in samples from cancer patients and healthy donors was measured using two different methods, the SYBR Green I fluorescence test and quantitative real-time PCR. Both methods revealed a statistically significant increase of cfDNA concentrations in cancer patients. Hypermethylation on cfDNA was detected for the (74.1%), (51.9%), (55.6%), and (62.9%) genes in patients with renal cancer. Promoter methylation of and genes was not found on cfDNA. Our results confirmed that the cfDNA level and methylation of CpG islands of , , and genes in blood plasma can be used as noninvasive diagnostic markers of cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048037PMC
http://dx.doi.org/10.1155/2016/3693096DOI Listing

Publication Analysis

Top Keywords

renal cancer
12
cancer patients
12
cancer
9
cell-free dna
8
dna blood
8
blood plasma
8
diagnostic markers
8
cfdna
8
patients renal
8
healthy donors
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!